Trillium Therapeutics Inc.

87 articles about Trillium Therapeutics Inc.

• Trillium Therapeutics Welcomes Dr. Helen Tayton-Martin To Its Board Of Directors

  10/12/2017

• Trillium Therapeutics Provides Additional Details On ASCO-SITC Conference Presentation On TTI-621

  2/24/2017

• Trillium Therapeutics Doses First Patient With TTI-621 In Phase 1 Solid Tumor Trial

  2/2/2017

• Trillium Therapeutics Advances TTI-621 Into Phase 1b Cohort Expansion Enrollment

  11/3/2016

• Trillium Therapeutics Inc. Acquires Fluorinov Pharma

  1/28/2016

• Trillium Therapeutics Inc. Acquires Privately-Held Fluorinov Pharma

  1/27/2016

• Trillium Therapeutics Inc. To Provide Update On CD47 Program At The 2015 American Association for Cancer Research Annual Meeting

  4/16/2015

• Trillium Therapeutics Inc. Announces Completion Of Public Offering Of Securities

  4/8/2015

• Trillium Therapeutics Inc. Announces Pricing Of Public Offering Of Securities

  4/1/2015

• Trillium Therapeutics Inc. To Present At The 5th Annual Cancer Immunotherapy Conference

  3/27/2015

• Trillium Therapeutics Inc. Announces Appointment of Eric L. Sievers, M.D. As Chief Medical Officer

  3/27/2015

• Trillium Therapeutics Inc. To List Common Shares On The NASDAQ Capital Market Under The Symbol TRIL

  12/18/2014

• Trillium Therapeutics Inc. Provides Corporate Update And Announces Reverse Stock Split For NASDAQ Listing

  11/14/2014

• Trillium Therapeutics Inc.'s Anti-CD47 Oncology Program Highlighted in Prestigious Journal

  9/7/2012

• Trillium Therapeutics Inc. Provides Update on Anti-CD47 Cancer Program

  4/5/2012

• First Patient Treated in Trillium Therapeutics Inc.'s Interstitial Cystitis/Bladder Pain Syndrome Clinical Trial

  3/28/2012

• Trillium Therapeutics Inc. to Commence Clinical Testing of TTI-1612 in Patients with Interstitial Cystitis/Bladder Pain Syndrome

  12/15/2011

• Trillium Therapeutics Inc. Raises Funds to Advance Urology Program Into Clinical Trials

  5/12/2011

• Trillium Therapeutics Inc.'s Cancer Stem Cell Program to be Highlighted at American Society of Hematology

  12/2/2010

• Trillium Therapeutics Inc. Expands Immunology Pipeline and Enters Stem Cell Field Through In-licensing of Two New Programs

  3/11/2010